Relugolix in the management of prostate cancer
暂无分享,去创建一个
[1] Shenglin Tang,et al. An Efficient UPLC-MS/MS Method Established to Detect Relugolix Concentration in Rat Plasma , 2022, Frontiers in Pharmacology.
[2] N. Shore,et al. Plain language summary of the HERO study comparing relugolix with leuprolide for men with advanced prostate cancer. , 2022, Future oncology.
[3] C. Ng,et al. Letter by Ng et al Regarding Article, "Cardiovascular Safety of Degarelix Versus Leuprolide in Patients With Prostate Cancer: The Primary Results of the PRONOUNCE Randomized Trial". , 2022, Circulation.
[4] T. Dorff,et al. Real-world experience with relugolix. , 2022, Journal of Clinical Oncology.
[5] D. George,et al. Impact of concomitant cardiovascular therapies on efficacy and safety of relugolix verus leuprolide in men with advanced prostate cancer: Subgroup analysis from the phase 3 HERO study. , 2022, Journal of Clinical Oncology.
[6] J. Aragon-Ching,et al. Advances with androgen deprivation therapy for prostate cancer , 2022, Expert opinion on pharmacotherapy.
[7] N. Fleshner,et al. Clinical Management of Prostate Cancer in High-Risk Genetic Mutation Carriers , 2022, Cancers.
[8] Jingjing Yu,et al. Pharmacokinetic Drug-Drug Interactions with Drugs Approved by the US Food and Drug Administration in 2020: Mechanistic Understanding and Clinical Recommendations , 2021, Drug Metabolism and Disposition.
[9] P. Noseworthy,et al. Real-world Cardiovascular Outcomes Associated With Degarelix vs Leuprolide for Prostate Cancer Treatment , 2021, JAMA network open.
[10] Deepak L. Bhatt,et al. Cardiovascular Safety of Degarelix Versus Leuprolide in Patients With Prostate Cancer , 2021, Circulation.
[11] D. Dearnaley,et al. Relugolix, an oral gonadotropin-releasing hormone antagonist for the treatment of prostate cancer. , 2021, Future oncology.
[12] H. Maeng,et al. Pharmaceutical Formulations with P-Glycoprotein Inhibitory Effect as Promising Approaches for Enhancing Oral Drug Absorption and Bioavailability , 2021, Pharmaceutics.
[13] A. Papatsoris,et al. Current and emerging gonadotropin-releasing hormone (GnRH) antagonists for the treatment of prostate cancer , 2021, Expert opinion on pharmacotherapy.
[14] M. Michel,et al. A year in pharmacology: new drugs approved by the US Food and Drug Administration in 2020 , 2021, Naunyn-Schmiedeberg's Archives of Pharmacology.
[15] F. Saad,et al. Relugolix: a novel androgen deprivation therapy for management of patients with advanced prostate cancer , 2021, Therapeutic advances in medical oncology.
[16] F. Saad,et al. Impact of concomitant prostate cancer therapy on efficacy and safety of relugolix versus leuprolide in men with advanced prostate cancer: Subgroup analysis from the phase III HERO study. , 2021 .
[17] M. Kirby,et al. Cardiovascular risk profiles of GnRH agonists and antagonists: real-world analysis from UK general practice , 2020, World Journal of Urology.
[18] F. Saad,et al. Oral Relugolix for Androgen-Deprivation Therapy in Advanced Prostate Cancer. , 2020, The New England journal of medicine.
[19] J. Sylvester,et al. The Oral Gonadotropin-releasing Hormone Receptor Antagonist Relugolix as Neoadjuvant/Adjuvant Androgen Deprivation Therapy to External Beam Radiotherapy in Patients with Localised Intermediate-risk Prostate Cancer: A Randomised, Open-label, Parallel-group Phase 2 Trial. , 2020, European urology.
[20] E. Schaeffer,et al. Surgical Versus Medical Castration for Metastatic Prostate Cancer: Use and Overall Survival in a National Cohort. , 2019, The Journal of urology.
[21] H. Akaza,et al. Phase I trial of TAK‐385 in hormone treatment‐naïve Japanese patients with nonmetastatic prostate cancer , 2019, Cancer medicine.
[22] A. Markham. Relugolix: First Global Approval , 2019, Drugs.
[23] M. Gizzi,et al. Advancing therapies in metastatic castration-resistant prostate cancer , 2018, Expert opinion on pharmacotherapy.
[24] A. Papatsoris,et al. Therapeutic outcomes of the LHRH antagonists , 2017, Expert review of pharmacoeconomics & outcomes research.
[25] R. Eckel,et al. The potential role of follicle-stimulating hormone in the cardiovascular, metabolic, skeletal, and cognitive effects associated with androgen deprivation therapy. , 2017, Urologic oncology.
[26] A. Sciarra,et al. A meta-analysis and systematic review of randomized controlled trials with degarelix versus gonadotropin-releasing hormone agonists for advanced prostate cancer , 2016, Medicine.
[27] H. Payne,et al. The role of gonadotrophin-releasing hormone antagonists in the treatment of patients with advanced hormone-dependent prostate cancer in the UK , 2016, World Journal of Urology.
[28] L. Klotz,et al. Degarelix monotherapy compared with luteinizing hormone-releasing hormone (LHRH) agonists plus anti-androgen flare protection in advanced prostate cancer: an analysis of two randomized controlled trials , 2016, Therapeutic advances in urology.
[29] F. Saad,et al. Second interim analysis (IA2) results from a phase II trial of TAK-385, an oral GnRH antagonist, in prostate cancer patients (pts). , 2016 .
[30] F. Saad,et al. Medical Castration Using the Investigational Oral GnRH Antagonist TAK-385 (Relugolix): Phase 1 Study in Healthy Males. , 2015, The Journal of clinical endocrinology and metabolism.
[31] A. Fabiano,et al. Strategies to Circumvent Testosterone Surge and Disease Flare in Advanced Prostate Cancer: Emerging Treatment Paradigms. , 2015, Journal of the National Comprehensive Cancer Network : JNCCN.
[32] M. Asada,et al. Suppression of the hypothalamic-pituitary-gonadal axis by TAK-385 (relugolix), a novel, investigational, orally active, small molecule gonadotropin-releasing hormone (GnRH) antagonist: studies in human GnRH receptor knock-in mice. , 2014, European journal of pharmacology.
[33] N. Vélez de Mendizábal,et al. Pharmacokinetic/Pharmacodynamic Model of the Testosterone Effects of Triptorelin Administered in Sustained Release Formulations in Patients with Prostate Cancer , 2012, Journal of Pharmacology and Experimental Therapeutics.
[34] E. Crawford,et al. A phase III extension trial with a 1-arm crossover from leuprolide to degarelix: comparison of gonadotropin-releasing hormone agonist and antagonist effect on prostate cancer. , 2011, The Journal of urology.
[35] T. Hitaka,et al. Discovery of 1-{4-[1-(2,6-difluorobenzyl)-5-[(dimethylamino)methyl]-3-(6-methoxypyridazin-3-yl)-2,4-dioxo-1,2,3,4-tetrahydrothieno[2,3-d]pyrimidin-6-yl]phenyl}-3-methoxyurea (TAK-385) as a potent, orally active, non-peptide antagonist of the human gonadotropin-releasing hormone receptor. , 2011, Journal of medicinal chemistry.
[36] L. Klotz,et al. Cardiovascular safety of degarelix: results from a 12-month, comparative, randomized, open label, parallel group phase III trial in patients with prostate cancer. , 2010, The Journal of urology.
[37] M. Marberger,et al. Effectiveness, pharmacokinetics, and safety of a new sustained-release leuprolide acetate 3.75-mg depot formulation for testosterone suppression in patients with prostate cancer: a Phase III, open-label, international multicenter study. , 2010, Clinical therapeutics.
[38] D. Jocham,et al. Degarelix for prostate cancer , 2009, Expert opinion on investigational drugs.
[39] J. Morote,et al. Individual variations of serum testosterone in patients with prostate cancer receiving androgen deprivation therapy , 2009, BJU international.
[40] Bruce Montgomery,et al. Androgen deprivation therapy: progress in understanding mechanisms of resistance and optimizing androgen depletion , 2009, Nature Clinical Practice Urology.
[41] D. Steyn,et al. Triptorelin 6-Month Formulation in the Management of Patients with Locally Advanced and Metastatic Prostate Cancer , 2009, Clinical drug investigation.
[42] F. Schröder,et al. The efficacy and safety of degarelix: a 12‐month, comparative, randomized, open‐label, parallel‐group phase III study in patients with prostate cancer , 2008, BJU international.
[43] B. Persson,et al. A 1-year, open label, randomized phase II dose finding study of degarelix for the treatment of prostate cancer in North America. , 2008, The Journal of urology.
[44] B. Tombal,et al. Degarelix: a novel gonadotropin-releasing hormone (GnRH) receptor blocker--results from a 1-yr, multicentre, randomised, phase 2 dosage-finding study in the treatment of prostate cancer. , 2008, European urology.
[45] K. Miller,et al. Management of advanced prostate cancer: can we improve on androgen deprivation therapy? , 2008, BJU international.
[46] A. Schally. Luteinizing hormone‐releasing hormone analogues and hormone ablation for prostate cancer: state of the art , 2007, BJU international.
[47] F. Debruyne,et al. Abarelix for injectable suspension: first-in-class gonadotropin-releasing hormone antagonist for prostate cancer. , 2006, Future oncology.
[48] J. Morote,et al. Failure to Maintain a Suppressed Level of Serum Testosterone during Long-Acting Depot Luteinizing Hormone-Releasing Hormone Agonist Therapy in Patients with Advanced Prostate Cancer , 2006, Urologia Internationalis.
[49] J. Rivier,et al. Iterative approach to the discovery of novel degarelix analogues: substitutions at positions 3, 7, and 8. Part II. , 2005, Journal of medicinal chemistry.
[50] D. Weckermann. Reply to Ph. Weston, B.-E. Persson , 2005 .
[51] P. Teillac,et al. Abarelix: the first gonadotrophin-releasing hormone antagonist for the treatment of prostate cancer , 2004, Expert opinion on pharmacotherapy.
[52] G. Reddy. Abarelix (Plenaxis): a gonadotropin-releasing hormone antagonist for medical castration in patients with advanced prostate cancer. , 2004, Clinical prostate cancer.
[53] F. Debruyne. Gonadotropin-releasing hormone antagonist in the management of prostate cancer. , 2004, Reviews in urology.
[54] Masataka Harada,et al. Discovery of a thieno[2,3-d]pyrimidine-2,4-dione bearing a p-methoxyureidophenyl moiety at the 6-position: a highly potent and orally bioavailable non-peptide antagonist for the human luteinizing hormone-releasing hormone receptor. , 2003, Journal of medicinal chemistry.
[55] John Trachtenberg,et al. A phase 3, multicenter, open label, randomized study of abarelix versus leuprolide plus daily antiandrogen in men with prostate cancer. , 2002, The Journal of urology.
[56] Jean E Rivier,et al. Pharmacological profile of a new, potent, and long-acting gonadotropin-releasing hormone antagonist: degarelix. , 2002, The Journal of pharmacology and experimental therapeutics.
[57] D. Gleason,et al. A phase 3, multicenter, open-label, randomized study of abarelix versus leuprolide acetate in men with prostate cancer. , 2001, Urology.
[58] M. Menon,et al. The gonadotropin-releasing hormone antagonist abarelix depot versus luteinizing hormone releasing hormone agonists leuprolide or goserelin: initial results of endocrinological and biochemical efficacies in patients with prostate cancer. , 2001, The Journal of urology.
[59] J. Rivier,et al. GnRH antagonists: a new generation of long acting analogues incorporating p-ureido-phenylalanines at positions 5 and 6. , 2001, Journal of medicinal chemistry.
[60] D. Jacqmin,et al. Three-Month Sustained-Release Form of Triptorelin in Patients with Advanced Prostatic Adenocarcinoma: Results of an Open Pharmacodynamic and Pharmacokinetic Multicenter Study , 1998, Hormone Research in Paediatrics.